Named catch-up gap: management identifies where the company visibly lags peers or its own potential, and is already clos
The model's full reasoning — Q2 2021 call → NOWe need to determine if management identifies a specific, named dimension on which the company currently underperforms relative to peers or its own potential, and describes work already underway to close that gap, with management treating it as a meaningful source of improvement not dependent on market conditions. Scan the transcript for such a diagnosis. Management discusses various topics: base business recovery, COVID testing, PAMA, investments, operational excellence, Clifton lab, etc. They mention "operational excellence" and "productivity initiatives" but do they name a specific gap? They talk about "we are focused on getting paid for what we do. We have made steady progress in reducing payer denials also patient concessions for our base revenues were down in the second quarter to 2019 levels" - that's a specific area (denials, concessions) but is it a gap? They say "down to 2019 levels" implying improvement, not underperformance. They mention "we continue to see a better than expected recovery in our base business" - not a gap. They mention "we are on track to deliver our targeted 3% improvement across the business" - that's a productivity target, but is it a named gap? They don't say "we underperform peers in productivity" or "our margins are lower than peers". They talk about "operational excellence" as a strategy, but no specific benchmark. They mention "we are on scheduled to complete the full transition to our new flagship laboratory in Clifton" - that's a facility, not a gap. They mention "we have engaged with businesses in the travel and [education] sectors" - not a gap. They mention "we continue to make progress on our two point strategy to accelerate growth and drive operational excellence" - general. They mention "we are focused on getting paid for what we do" - that's a general improvement. No specific named dimension where they underperform. They don't say "our margins are lower than peers" or "our Northeast region lags" - they do say "slower recovery in the Northeast" but that's attributed to external conditions (pandemic) not a management-owned gap. They say "we do see much of the country after '19 levels. And as I said before, the Northeast is stubborn" - that's a regional lag but they attribute it to the pandemic, not to their own inefficiency. They don't describe work to close that specific gap beyond general recovery.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| MEG | Montrose Environmental Group, Inc. | Q3 2023 | 2023-11-08 | C+ |
| RVLV | Revolve Group, Inc. | Q3 2023 | 2023-11-01 | C |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| SWK | Stanley Black & Decker, Inc. | Q1 2023 | 2023-05-04 | D |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| STC | Stewart Information Services Corporation | Q1 2022 | 2022-04-29 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ACHC | Acadia Healthcare Company, Inc. | Q4 2017 | 2018-02-22 | C+ |
| ADNT | Adient plc | Q1 2018 | 2018-01-29 | D |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| STKL | SunOpta Inc. | Q2 2017 | 2017-08-09 | C+ |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| ABM | ABM Industries Incorporated | Q2 2017 | 2017-06-08 | B |
| PPG | PPG Industries, Inc. | Q1 2017 | 2017-04-20 | C |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| SXT | Sensient Technologies Corporation | Q4 2016 | 2017-02-10 | A |
| BC | Brunswick Corporation | Q3 2016 | 2016-10-28 | B+ |
| SON | Sonoco Products Company | Q4 2015 | 2016-02-11 | B |
HOLX · Q4 2017 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management explicitly diagnosing Cynosure’s commercial organization as the specific underperforming dimension (salesforce turnover, recruiting, and productivity lagging behind the company’s international business and its own best operations). They then describe concrete, already-executing actions—stopping voluntary turnover, rehiring high performers, instituting 90-day reviews, new compensation, and building “Cynosure 2.0”—as the mechanism to close the gap.
STKL · Q2 2017 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management identifying a specific named gap in the bars segment, where operational issues at a particular facility are causing inefficient production and gross margin losses. They describe a rapid recovery team already executing systematic identification and correction of these issues, treating the gap as closable through their own operational efforts rather than external market improvements — this aligns with the criteria for a meaningful source of improvement.
ADNT · Q1 2018 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management explicitly naming the Seat Structures and Mechanisms (SS&M) business as the specific underperforming dimension. They state it is “destroyed shareholder value” when run as currently organized, and that it is “impacting our financial results” with “significant impact.